



Highlights from Market Access

Stakeholders Association Meeting

24 October 2011



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

Key Highlights 2011

- Market Access Advisory Committee
- Private sector study follow on
- Patient study
- Pediatrics
- Drug sensitivity testing



Access Advisory Committee

MEMBERS



Jaap Broekmans
Johns Hopkins Bloomberg
School of Public Health
[Download bio](#) ▶



Puneet Dewan
World Health Organization
[Download bio](#) ▶




Elizabeth Gardiner
TB Alliance
[Download bio](#) ▶



Cheri Grace
HLSP
[Download bio](#) ▶



Michael Kimmerling
Bill & Melinda Gates
Foundation
[Download bio](#) ▶



Carl Mendel
TB Alliance
[Download bio](#) ▶



Dyah Mustikawati
Ministry of Health,
Indonesia
[Download bio](#) ▶



David Ripin
Clinton Health Access
Initiative
[Download bio](#) ▶



Joseph Sitienei
Ministry of Public Health
and Sanitation, Kenya
[Download bio](#) ▶



William Wells
TB Alliance
[Download bio](#) ▶



Clifford Samuels
Gilead International
[Download bio](#)



Access Advisory Committee (AAC)

- Convened to help
 - Refine our market access plans & strategies
 - Determine where we should focus our efforts
 - Ensure that our drug development is guided by market understanding
 - Offer critical thinking on ways to reduce barriers to access
 - Connect us to others who can help with access
 - Encourage the market to anticipate and introduce new regimens




First AAC Meeting

- Review of regimens closest to market (REMOx & PaMZ)
- Discussion of how to increase adoption
 - Don't go it alone: Work with others to understand resistance profile for all drugs
 - Country perspective: can combine both DS & MDR budgets to pay for new regimens
 - “Protect drugs not by *not using* them, but by *using them well*”




Significant Private Sector Market Size: # of 1st line cases potentially treated



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

Market Clutter: Many different formulations



- 111 total dosages (70 in India alone) vs 14 needed.



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

Private Sector

- How to prepare for the introduction of new TB regimens in the private market?
- Disseminate private sector study findings
 - Published in PLoSOne:
<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0018964>
 - Document the scale of private market
 - Generate awareness of private sector as part of TB treatment system



Private Sector: Next Steps

- Advocate for attention and resources commensurate with size of market: PPM so far is insufficient and not to scale
- Circulate draft PPM paper for broader discussion
- Identify private sector channels that can deliver TB treatment well



Patient Perspective

- How can we be sure patients' voices are heard in the discussions on development and adoption of new regimens?
- Patient study
 - In partnership with Liverpool School of Tropical Medicine
 - Initially with BRAC in Bangladesh and NIMR Mwanza in Tanzania
 - Document the potential benefits of shorter regimens for patients for use in decision-making
 - Quantify patient costs for budgeting & cost effectiveness



Pediatrics

- What treatments work for children? How can they be incorporated into healthcare systems?
- Goals
 - Gain better understanding of current pediatric treatments and how they can be improved
 - Work with a variety of partners to explore ways to incorporate new drugs into pediatric TB scale up
 - Evaluate potential roles for us to help ensure that new & existing treatments are appropriate for children



Drug Sensitivity Testing

- Current testing is insufficient and does not allow us to know whether treatments will work
- Build on excitement of GeneXpert
 - Develop rapid diagnostics for FQ, PZA, and other commonly used drugs
 - Scale up access to DST
- Expand surveillance data to help understand resistance patterns by country/region
- Advocacy for expanded focus on DST

